A detailed history of Pdt Partners, LLC transactions in 89bio, Inc. stock. As of the latest transaction made, Pdt Partners, LLC holds 80,918 shares of ETNB stock, worth $681,329. This represents 0.06% of its overall portfolio holdings.

Number of Shares
80,918
Previous 169,245 52.19%
Holding current value
$681,329
Previous $1.25 Million 50.48%
% of portfolio
0.06%
Previous 0.12%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

SELL
$7.03 - $10.05 $620,938 - $887,686
-88,327 Reduced 52.19%
80,918 $620,000
Q3 2024

Nov 14, 2024

BUY
$7.36 - $9.66 $1.25 Million - $1.63 Million
169,245 New
169,245 $1.25 Million
Q2 2022

Aug 15, 2022

SELL
$2.09 - $4.02 $27,376 - $52,657
-13,099 Reduced 56.04%
10,274 $33,000
Q1 2022

May 16, 2022

BUY
$3.45 - $14.99 $80,636 - $350,361
23,373 New
23,373 $88,000

Others Institutions Holding ETNB

About 89bio, Inc.


  • Ticker ETNB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,484,500
  • Market Cap $391M
  • Description
  • 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...
More about ETNB
Track This Portfolio

Track Pdt Partners, LLC Portfolio

Follow Pdt Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pdt Partners, LLC with notifications on news.